We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04588662
Previous Study | Return to List | Next Study

A Prospective Natural History Study in Uveal Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04588662
Recruitment Status : Recruiting
First Posted : October 19, 2020
Last Update Posted : June 30, 2022
Sponsor:
Information provided by (Responsible Party):
Richard D. Carvajal, Columbia University

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The overall objective of this proposal is to develop and utilize a multicenter UM registry that will, in a longitudinal fashion, capture prospective data in order to characterize the natural history of UM and provide data that will be used to support the development of novel therapies for this disease. The care of patients with UM requires a multi-disciplinary team of physicians that commonly requires the involvement of both radiation oncology and interventional radiology, and is typically directed by an ophthalmologic oncologist at time of initial diagnosis of primary disease. Overall management is transitioned to a medical oncologist when distant recurrence is identified. In the case that a patient presents with metastasis at the time of diagnosis, a medical oncologist typically directs overall management. The management of surveillance for the development of metastasis following the treatment of primary disease is variable and, if performed at all, is managed by either an ophthalmologic oncologist or medical oncologist. Thus, the successful development of a registry that aims to capture the data regarding the full natural history of UM requires a collaborative effort including leaders from both the UM ophthalmologic oncology and medical oncology fields. To this end, the investigators have built an initial consortium of key ophthalmologic oncology and medical oncology leaders from multiple major UM centers in the United States.

Condition or disease
Uveal Melanoma

Detailed Description:

Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, accounting for 85% to 95% of ocular melanoma cases. However, UM represents only about 3% to 5% of all melanomas in the United States (US). UM most commonly arises from choroidal melanocytes (85-90%), but can also arise from the iris (3-5%) and ciliary body (5-8%). The median age of diagnosis is approximately 62; however, the peak range for diagnosis is between 70 and 79. Males have a 30% greater incidence than females. A variety of putative risk factors have been identified, including the presence of light eyes, fair skin, an inability to tan, ocular melanocytosis, dysplastic nevus syndrome, and germline BRCA1-associated protein 1 (BAP1) mutations.

Importantly, there are no recent or on-going multi-center natural history studies being conducted in this disease, and this effort is the only one to be launched with the goal of capturing the complete course of this disease, from diagnosis, initial management, surveillance, and treatment of recurrent disease in a national and international setting. This registry is especially important in providing such needed data.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 700 participants
Observational Model: Other
Time Perspective: Prospective
Target Follow-Up Duration: 3 Years
Official Title: A Prospective Natural History Study in Uveal Melanoma
Actual Study Start Date : May 6, 2021
Estimated Primary Completion Date : July 2023
Estimated Study Completion Date : July 2023

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
Uveal Melanoma
Diagnosis of uveal melanoma Ability to provide written informed consent for participation in the prospective registry OR an institutional waiver by the IRB/ethics committee for retrospective data collection without written informed consent


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Relapse-free Survival Rate [ Time Frame: Up to Five years ]
    Document the relapse-free survival of patients with uveal melanoma from the time of diagnosis of primary disease

  2. Overall Survival Rate [ Time Frame: Up to Five years ]
    document the overall survival of patients with uveal melanoma from the time of diagnosis of primary disease

  3. Overall Survival Rate of Patients with Uveal Melanoma [ Time Frame: Up to Five years ]
    document the overall survival of patients with uveal melanoma from the time of development of metastatic disease


Biospecimen Retention:   Samples Without DNA
Residual tissue samples from clinical care biopsies that would otherwise be discarded will be collected.

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
  • Diagnosis of uveal melanoma
  • Male/Female over the age of 18 years of age
Criteria

Inclusion Criteria

  • Diagnosis of uveal melanoma
  • Ability to provide written informed consent for participation in the prospective registry OR an institutional waiver by the IRB/ethics committee for retrospective data collection without written informed consent

Exclusion Criteria

*None

Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04588662


Contacts
Layout table for location contacts
Contact: Research Nurse Navigator 212-342-5162 cancerclinicaltrials@cumc.columbia.edu

Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital Not yet recruiting
Boston, Massachusetts, United States, 02114
Contact: Ryan Sulivan, MD         
United States, New York
Memorial Sloan Kettering Cancer Center Not yet recruiting
New York, New York, United States, 10065
Contact: Alex Shoushtari, MD         
United States, Pennsylvania
Thomas Jefferson University Hospital Not yet recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Marlana Orloff, MD         
United States, Texas
MD Anderson Cancer Center Not yet recruiting
Houston, Texas, United States, 77030
Contact: Sapna Patel, MD         
Australia
Royal Adelaide Hospital Recruiting
Adelaide, Australia
Contact: David Sa, MD         
Chatswood Eye Specialists Not yet recruiting
Chatswood, Australia
Contact: Michael Giblin, MD         
Royal Victorian Eve and Ear Hospital Not yet recruiting
East Melbourne, Australia
Contact: John Mckenzie, MD         
Perth Retina Not yet recruiting
Subiaco, Australia
Contact: Tim Isaacs, MD         
Dr. Conway Private Rooms Not yet recruiting
Sydney, Australia
Contact: Max Conway, MD         
St. Vincent's Hospital Not yet recruiting
Sydney, Australia
Contact: Anthony Joshua, MD         
Canada
Pricness Margaret Cancer Center Not yet recruiting
Toronto, Canada
Contact: Marcus Bulter, MD         
Germany
Erlangen Not yet recruiting
Erlangen, Germany
Contact: Markus Heppt, MD         
United Kingdom
Clatterbridge Cancer Centre Not yet recruiting
Birkenhead, United Kingdom
Contact: Joseph Sacco, MD         
Mount Vernon Cancer Centre Not yet recruiting
Northwood, United Kingdom
Contact: Heather Shaw, MD         
Sheffield Not yet recruiting
Sheffield, United Kingdom
Contact: Shobaha Silva, MD         
Sponsors and Collaborators
Richard D. Carvajal
Investigators
Layout table for investigator information
Principal Investigator: Richard D. Carvajal, MD Columbia University
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Richard D. Carvajal, Associate Professor of Medicine, Columbia University
ClinicalTrials.gov Identifier: NCT04588662    
Other Study ID Numbers: AAAR5976
First Posted: October 19, 2020    Key Record Dates
Last Update Posted: June 30, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Richard D. Carvajal, Columbia University:
Uveal Melanoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Uveal Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
 Neoplasms, Nerve Tissue
Nevi and Melanomas
Eye Neoplasms
Neoplasms by Site
Eye Diseases
Uveal Diseases